

Table S1. Characteristics in patients with or without renal outcome around 12 months

Characteristics	With or without renal outcome around 12 months (n=122)		
	with n=72	without n=50	P value
Age ys mean±SD	34.5±11.1	34.0±10.8	0.796
Female n (%)	63(87.5)	46(92.0)	0.428
SLE duration years median (IQR)	6.1(1.0-11.3)	6.3(2.9-10.3)	0.879
LN duration years median (IQR)	1.9(0.1-7.3)	1.9(0.0-7.9)	0.773
Follow up months median (IQR)	13.2(11.8-16.4)	5.6(6.9-10.2)	<0.0001
Renal biopsy n (%)			
III or IV	25(52.1)	14(42.4)	0.393
V	6(12.5)	4(12.1)	0.959
III/IV+V	16(33.3)	14(42.4)	0.405
Proteinuria g mean±SD	3.2±2.2	3.3±2.4	0.851
Proteinuria≥3g n (%)	29(40.3)	22(44.0)	0.682
albumin g/L mean±SD	30.7±5.7	29.0±7.2	0.139
Estimated GFR — ml per minute per 1.73 m ²	103.4±36.8	97.9±35.3	0.405
Estimated GFR category — n (%)			
≥60 ml/min/1.73 m ²	65(90.3)	42(84.0)	0.299
≥90 ml/min/1.73 m ²	45(62.5)	30(60.0)	0.780
SLEDAI-2K mean±SD	11.6±4.1	11.7±4.5	0.951
Clinical SLEDAI-2K mean±SD	8.8±3.4	8.7±4.1	0.926
Serology			
Positive antinuclear antibody n (%)	69(98.6)	46(100)	0.416
Positive anti-dsDNA antibody n (%)	48(66.7)	31(64.6)	0.814
Positive anti-nucleosome antibody n (%)	26(37.1)	18(39.1)	0.829
Positive anti-histone antibody n (%)	26(37.1)	18(39.1)	0.829
Positive anti-Sm antibody n (%)	21(30.0)	16(34.8)	0.589
Positive anti-RNP antibody n (%)	33(47.1)	22(47.8)	0.943
Positive anti-ribosomal P protein n (%)	21(30.0)	20(43.5)	0.137
Positive anti-SSA/Ro60 antibody n (%)	44(62.9)	25(54.3)	0.361
Positive anti-SSB antibody n (%)	10(14.3)	12(26.1)	0.113
Positive anti-Ro52 antibody n (%)	31(44.3)	19(41.3)	0.751
Low Complement C3 n (%)	47(67.1)	35(71.4)	0.619
Low Complement C4 n (%)	29(42.0)	24(51.1)	0.338
Low Complement n (%)	50(72.5)	35(71.4)	0.902
Baseline therapy			
Prednisone dosage/mg mean±SD	33.6±23.0	30.2±18.1	0.357
ACEI/ARB	42(58.3)	26(52.2)	0.489
hydroxychloroquine n (%)	59(81.9)	36(72.0)	0.193
mycophenolate mofetil n (%)	35(48.6)	27(54.0)	0.558
calcineurin inhibitors n (%)	22(30.6)	18(36.0)	0.529
cyclophosphamide n (%)	7(9.7)	10(20.0)	0.107
Others n (%)	17(23.6)	8(16.0)	0.306
No classic IS n (%)	11(15.3)	5(10.0)	0.396
NRR at 6 months n (%)	27(40.3)	28(56.0)	0.092

SD, standard

deviation; SLE, Systemic lupus erythematosus; LN, lupus nephritis; IQR, interquartile range; GFR, glomerular filtration rate; SLEDAI-2K,

systemic Lupus Erythematosus Disease Activity Index 2000.IS, immunosuppressive agents; NRR, no renal response.ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers;

Table S2. Renal response rates in different renal pathology types

		Proliferative	membranous	Mixed	P value
Total biopsy	CRR6	13/37(35.1)	2/9(22.2)	8/29(27.6)	0.677
N=81	PRR6	6/37(16.2)	2/9(22.2)	3/29(10.3)	0.633
	NRR6	18/37(48.6)	5/9(55.6)	18/29(62)	0.553
	PERR6	15/37(40.5)	5/9(55.6)	10/29(34.5)	0.527
	CRR12	14/25(56.0)	5/6(83.3)	6/16(37.5)	0.146
	PRR12	5/25(20.0)	0/6(0.0)	4/16(25.0)	0.409
	NRR12	6/25(24.0)	1/6(16.7)	7/16(43.8)	0.303
	PERR12	14/25(56.0)	5/6(83.3)	6/16(37.5)	0.146
	Biopsy within 6 months	CRR6	9/21(42.9)	1/7(14.3)	4/10(40.0)
N=40	PRR6	2/21(9.5)	2/7(28.6)	2/10(20.0)	0.446
	NRR6	10/21(47.6)	4/7(57.1)	4/10(40.0)	0.784
	PERR6	11/21(52.4)	3/7(42.9)	4/10(40.0)	0.784
	CRR12	10/14(71.4)	4/5(80.0)	3/4(75.0)	0.931
	PRR12	0/14(0.0)	0/5(0.0)	1/4(25.0)	0.083
	NRR12	4/14(28.6)	1/5(20.0)	0/4(0.0)	0.471
	PERR12	10/14(71.4)	4/5(80.0)	3/4(75.0)	0.931

CRR, complete renal response; PRR, partial renal response; NRR, no renal response; PERR, primary efficacy renal response.

Table S3. Characteristics in patients with renal outcome around 12 months

Characteristics	Renal outcome around 12 months (N=72)		
	CRR n=40	Non-CRR n=32	P value
Age ys mean±SD	34.8±11.4	34.3±11.0	0.860
Female n (%)	37(92.5)	26(81.3)	0.151
SLE duration years median (IQR)	3.5(0.5-11.5)	8.7(3.9-11.3)	0.056
LN duration years median (IQR)	1.0(0.0-6.1)	4.0(0.4-9.2)	0.086
Follow up months median (IQR)	13.2(11.6-16.4)	13.2(12.0-17.4)	0.759
Renal biopsy n (%)			
III or IV n (%)	14(53.8)	11(50.0)	0.790
V n (%)	5(19.2)	1(4.5)	0.125
III/IV+V n (%)	6(23.1)	10(45.5)	0.101
Proteinuria ^a g mean±SD	2.7±1.9	4.1±2.6	0.020
Proteinuria ^a ≥3g n (%)	12(30.0)	17(53.1)	0.047
albumin g/L mean±SD	30.6±5.0	30.1±6.4	0.741
Estimated GFR — ml per minute per 1.73 m2	108.4±33.3	97.3±40.4	0.217
Estimated GFR category — n (%)			
≥60 ml per minute per 1.73 m2	37(92.5)	28(87.5)	0.477
≥90 ml per minute per 1.73 m2	29(72.5)	16(50.0)	0.050
SLEDAI-2K mean±SD	12.1±4.3	11.0±3.9	0.235
Clinical SLEDAI-2K mean±SD	9.1±3.5	8.4±3.3	0.205

Serology

Positive antinuclear antibody n (%)	38(100)	31(96.9)	0.272
Positive anti-dsDNA antibody n (%)	27(67.5)	21(65.6)	0.867
Positive anti-nucleosome antibody n (%)	16(42.1)	10(31.3)	0.349
Positive anti-histone antibody n (%)	16(42.1)	10(31.3)	0.349
Positive anti-Sm antibody n (%)	12(31.6)	9(28.1)	0.753
Positive anti-RNP antibody n (%)	18(47.4)	15(46.9)	0.967
Positive anti-ribosomal P protein n (%)	14(36.8)	7(21.9)	0.173
Positive anti-SSA/Ro60 antibody n (%)	22(57.9)	22(68.8)	0.349
Positive anti-SSB antibody n (%)	3(7.9)	7(21.9)	0.096
Positive anti-Ro52 antibody n (%)	17(44.7)	14(43.8)	0.934
Low Complement C3 n (%)	28(70.0)	19(63.3)	0.557
Low Complement C4 n (%)	16(41.0)	13(43.3)	0.847
Low Complement n (%)	30(76.9)	20(66.7)	0.344

Baseline therapy

Prednisone dosage/mg mean±SD	35.9±17.0	30.8±28.8	0.378
ACEI/ARB n(%)	20(50.0)	22(68.8)	0.109
hydroxychloroquine n (%)	31(77.5)	28(87.5)	0.273
mycophenolate mofetil n (%)	22(55.0)	13(40.6)	0.225
calcineurin inhibitors n (%)	6(22.6)	13(40.6)	0.097
cyclophosphamide n (%)	4(10.0)	3(9.4)	0.929
Others n (%)	8(20.0)	9(28.1)	0.420
No classic IS n (%)	6(15.0)	5(15.9)	0.942
NRR at 6 months n (%)	6(16.2)	21(70.0)	0.000

SD, standard

deviation; SLE, Systemic lupus erythematosus; LN, lupus nephritis; IQR, interquartile range; GFR, glomerular filtration rate; SLEDAI-2K, systemic Lupus Erythematosus Disease Activity Index 2000; IS, immunosuppressive agents; NRR, no renal response; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers;

Table S4. Characteristics in patients in main serotypes

Characteristics	anti-dsDNA-/SSA+ (n=20)	anti-dsDNA+/SSA- (n=31)	P value
Age ys mean ± SD	36.2±9.3	30.0±9.8	0.028
Female n (%)	18(90.0)	27(87.1)	0.753
SLE duration years median (IQR)	2.8(0.5-10.1)	6.9(4.6-10.6)	0.071
LN duration years median (IQR)	1.0(0.0-5.4)	5.3(0.1-8.0)	0.041
Follow up months median (IQR)	11.5(6.4-15.7)	11.4(7.4-16.2)	0.839
Renal biopsy			
III or IV n (%)	9(52.9)	10(47.6)	0.744
V n (%)	2(11.8)	2(9.5)	0.823
III/IV+V n (%)	5(29.4)	9(42.9)	0.393
Proteinuria ^a g mean ± SD	3.4±2.6	3.0±1.5	0.533
Proteinuria ^a ≥ 3g n (%)	8(40.0)	15(48.4)	0.557
albumin g/L mean ± SD	31.0±7.1	29.4±6.9	0.471
Estimated GFR — ml/min/1.73 m ²	108.0±42.5	105.1±38.4	0.808
Estimated GFR category — n (%)			
≥60 ml/min/1.73 m ²	18(90.0)	27(87.1)	0.753

≥90 ml/min/1.73 m ²	13(65.0)	21(67.7)	0.839
SLEDAI-2K mean ± SD	9.2±4.0	13.6±4.0	0.000
Clinical SLEDAI-2K mean ± SD	7.5±3.6	10.0±3.9	0.022
Serology			
Positive antinuclear antibody n (%)	20(100)	31(100)	/
Positive anti-dsDNA antibody n (%)	0(0)	31(100)	0.000
Positive anti-neucleosome antibody n (%)	5(25.0)	13(41.9)	0.217
Positive anti-histone antibody n (%)	12(38.7)	7(35.0)	0.789
Positive anti-Sm antibody n (%)	8(40.0)	10(32.3)	0.572
Positive anti-RNP antibody n (%)	11(55.0)	15(48.4)	0.645
Positive anti-ribosomal P protein n (%)	8(40.0)	12(38.7)	0.927
Positive anti-SSA/Ro60 antibody n (%)	20(100)	0(0)	0.000
Positive anti-SSB antibody n (%)	8(40.0)	0(0)	0.000
Positive anti-Ro52 antibody n (%)	13(65.0)	1(3.2)	0.000
Low Complement C3 n (%)	14(73.7)	21(67.7)	0.656
Low Complement C4 n (%)	7(36.8)	17(56.7)	0.176
Low Complement n (%)	14(73.7)	24(77.4)	0.764
Baseline therapy			
Prednisone dosage/mg mean ± SD	31.8(18.1)	31.0(18.4)	0.884
ACEI/ARB	11(50)	18(56.3)	0.651
hydroxychloroquine n (%)	13(65.0)	24(77.4)	0.332
mycophenolate mofetil n (%)	12(60.0)	19(61.3)	0.927
calcineurin inhibitors n (%)	6(30.0)	11(35.5)	0.685
cyclophosphamide n (%)	2(10.0)	1(3.2)	0.315
Others n (%)	4(20.0)	5(16.1)	0.723
No classic IS n (%)	5(25.0)	4(12.9)	0.268
NRR at 6 months n (%)	15(75.0)	9(29.0)	0.001

SD, standard deviation; SLE, Systemic lupus erythematosus; LN, lupus nephritis; IQR, interquartile range; GFR, glomerular filtration rate; SLEDAI-2K, systemic Lupus Erythematosus Disease Activity Index 2000. IS, immunosuppressive agents; NRR, no renal response. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers;